Antiviral Agents

Characteristics of Viruses

  • Viruses cause a variety of conditions in living organisms.

  • Each virus consists of a single virus particle containing either DNA or RNA enclosed in a protein coat.

  • To replicate and carry on metabolic processes, a virus must enter a host cell.

  • The replication process of a virus occurs within the host cell, leading to the death of the host cell and the release of new virus particles into the body.

  • Developing effective antiviral drugs poses challenges because they must destroy the virus without harming the human host’s cells.

  • Interferons are proteins released by the host that act to prevent viral replication, providing a defense mechanism against infections.

Stages of Virus Replication

  • Step A: Virus Adherence

    • A virus adheres to the surface of the host cell.

  • Step B: Virus Entry

    • The virus enters the host cell through a process known as pinocytosis.

  • Step C: Coat Shedding

    • The virus sheds its protein coat once inside the cell.

  • Step D: Replication of Viral Nucleic Acids

    • The viral nucleic acids (either DNA or RNA) are replicated inside the host cell.

  • Step E: Synthesis of Viral Proteins and Capsid

    • Viral proteins, including those that will form the capsid, are synthesized.

  • Step F: Assembly of New Virions

    • New virus particles (virions) are assembled.

  • Step G: Release

    • The new virions are released from the host cell, often causing the cell to die.

Antivirals Across the Lifespan

  • Children

    • Children are very sensitive to the effects of most antiviral drugs.

    • Many antiviral medications have not been proven safe and effective for pediatric use.

  • Adults

    • It is crucial to understand that antivirals are specifically used for treating viral infections.

    • Antiviral drugs can have significant adverse effects on fetal development.

  • Older Adults

    • Older adults may be more susceptible to the adverse effects of antivirals.

    • Caution is needed when administering antivirals to patients with hepatic or renal dysfunction.

Agents for Influenza A and Respiratory Viruses

  • Prevention through vaccination is deemed the best option.

  • Some antiviral drug therapies are available for treating infections.

  • Action of Antivirals

    • They inhibit viral enzymes, slow the spread of the virus, or induce viral death.

  • Pharmacokinetics

    • The pharmacokinetics vary depending on the specific drug used.

  • Contraindications and Cautions

    • Oseltamivir: Use with caution in individuals with renal dysfunction.

    • Antiviral use during pregnancy or breastfeeding requires careful consideration.

  • Adverse Effects

    • Adverse effects may arise, linked to effects on dopamine levels in the body.

  • Drug–Drug Interactions

    • Caution should be observed with nasal influenza vaccines in combination with neuraminidase inhibitors.

Question #1

  • Statement: Treatment of a viral infection is difficult without serious toxic effects for the host.

  • True/False: True

    • Rationale: Since a virus must enter human cells to survive, treating viral infections often leads to serious toxic effects for the host.

Agents for Herpes and Cytomegalovirus

  • Action

    • These agents inhibit viral DNA replication by competing with viral substrates, forming shorter and ineffective DNA chains.

  • Pharmacokinetics

    • Pharmacokinetics varies with specific drugs used.

  • Contraindications and Cautions

    • Some antiviral drugs are highly toxic; extreme caution is required for patients who are pregnant or lactating.

    • Known allergies, renal disease, and CNS disorders are significant cautions.

  • Adverse Effects

    • Common adverse effects include nausea, vomiting, headache, depression, paresthesia, neuropathy, rash, and hair loss; renal dysfunction is also a concern.

  • Drug–Drug Interactions

    • Be cautious when prescribing nephrotoxic drugs and zidovudine concurrently with herpes antivirals.

Agents for HIV and AIDS

  • Antiretroviral Agents

    • Include various classes:

      • Nonnucleoside reverse transcriptase inhibitors (NNRTIs)

      • Nucleoside reverse transcriptase inhibitors (NRTIs)

      • Protease inhibitors

      • Fusion inhibitors

      • CCR5 coreceptor antagonists

      • Integrase strand transfer inhibitors

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

  • Action

    • They bind directly to HIV reverse transcriptase, blocking both RNA- and DNA-dependent DNA polymerase activities.

  • Pharmacokinetics

    • Rapidly absorbed from the gastrointestinal (GI) tract, metabolized in the liver, and excreted in urine and/or feces.

  • Contraindications and Cautions

    • Caution is exercised during pregnancy and lactation.

  • Adverse Effects

    • These medications have gastrointestinal effects, and may cause dizziness, blurred vision, headache, or flu-like syndrome which may relate to the underlying disease.

  • Drug–Drug Interactions

    • Notable interactions include:

      • Delavirdine with antiarrhythmics, clarithromycin, anti-TB drugs, and other medications.

      • Efavirenz interactions with midazolam and rifabutin, among others.

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

  • Action

    • Compete with naturally occurring nucleosides that viruses utilize to build DNA chains.

  • Pharmacokinetics

    • Generally rapidly absorbed from the GI tract, metabolized by the liver, and excreted mainly via the urine.

  • Contraindications and Cautions

    • Cautions include pregnancy, breastfeeding, hepatic dysfunction, and potential for bone marrow suppression.

  • Adverse Effects

    • Include hypersensitivity reactions, pancreatitis, hepatomegaly, neurological issues, and bone marrow suppression.

Protease Inhibitors

  • Action

    • Protease inhibitors block the activity of protease, which is essential for HIV to fuse with host cells and inject itself.

  • Pharmacokinetics

    • Varies by drug but generally, these agents have different absorption and metabolism profiles.

  • Contraindications and Cautions

    • Caution is warranted in those with hepatic dysfunction or those being treated with antidiabetic agents.

  • Adverse Effects

    • Can cause gastrointestinal effects, changes in liver function, increased cholesterol and triglyceride levels, fat redistribution, and Stevens-Johnson syndrome.

Fusion Inhibitor

  • Action

    • Prevents the fusion of the HIV virus with the human cell membrane.

  • Pharmacokinetics

    • Administered subcutaneously, metabolized in the liver, and not primarily excreted.

  • Contraindications and Cautions

    • Hypersensitivity, pregnancy, or breast feeding, and individuals with lung disease.

  • Adverse Effects

    • May experience insomnia, depression, peripheral neuropathy, nausea, diarrhea, pneumonia, and site reaction from injections.

CCR5 Coreceptor Antagonist

  • Action

    • Blocks the receptor site on host cell membranes that HIV requires for entry.

  • Pharmacokinetics

    • Rapidly absorbed from the GI tract, metabolized in the liver, and primarily excreted through feces.

  • Contraindications and Cautions

    • Known drug allergies, breastfeeding, liver disease.

  • Adverse Effects

    • May cause severe hepatotoxicity, CNS effects, and upper respiratory infections (URIs).

  • Drug–Drug Interactions

    • Can alter serum levels and increase toxicity when interacting with cytochrome P-450 inhibitors and inducers as well as St. John’s wort.

Integrase Strand Transfer Inhibitors

  • Action

    • Inhibit the activity of the integrase enzyme needed for viral replication.

  • Pharmacokinetics

    • Rapidly absorbed from the GI tract, metabolized by the liver, and excreted in urine and feces.

  • Contraindications and Cautions

    • Known hypersensitivities; risks associated with rhabdomyolysis, myopathy, and pregnancy.

  • Adverse Effects

    • Potential liver failure, renal impairment, suicidal ideation, headaches, dizziness, insomnia, and weight gain.

  • Drug–Drug Interactions

    • Serum levels may decrease if taken in conjunction with rifampin or St. John’s wort.

Question #2

  • Scenario: A patient with herpes simplex is prescribed an antiviral medication.

    • Teaching Points:

      • Use absorbent pads when applying the drug topically to reduce exposure risk.

      • Expect GI upset, nausea, and vomiting as potential adverse effects.

      • Start taking the medication promptly for improved effectiveness of antiviral action.

      • Adhere to dosing protocols to enhance antiviral efficacy.

Answer to Question #2

  • Correct Answer: C. Start taking the medicine as soon as possible to improve effectiveness of antiviral activity.

  • Rationale: Rapid administration of the drug following diagnosis is crucial for maximizing antiviral effectiveness.

Question #3

  • Scenario: A patient with HIV reports pain at the injection site. What type of drug is likely being used?

    • Options:

    • Integrase inhibitor

    • Fusion inhibitor

    • Reverse transcriptase inhibitor

    • Protease inhibitor

Answer to Question #3

  • Correct Answer: A. Fusion inhibitor

  • Rationale: Fusion inhibitors like enfuvirtide (Fuzeon) are administered subcutaneously, which can lead to injection site reactions, while other drug classes are taken orally.

Anti-Hepatitis B Agents

  • Action

    • These agents inhibit reverse transcriptase in hepatitis B, leading to DNA chain termination.

  • Pharmacokinetics

    • Rapid absorption from the GI tract, liver metabolism, and urinary excretion.

  • Contraindications and Cautions

    • Known allergies, renal impairment, severe liver disease, pregnancy, and HIV infection with tenofovir alafenamide.

  • Adverse Effects

    • Side effects can include headache, dizziness, nausea, diarrhea, elevated liver enzymes, hepatomegaly with steatosis, and renal impairment.

  • Drug–Drug Interactions

    • Heightened risk of renal toxicity if taken with other nephrotoxic drugs.

Anti-Hepatitis C Agents

  • Action

    • The mechanism of action varies significantly between agents.

  • Pharmacokinetics

    • These agents are readily absorbed from the GI tract, metabolically processed in the liver, and subsequently excreted via urine and/or feces.

  • Contraindications and Cautions

    • Known allergies, severe liver disease, pregnancy, and coinfection of HIV and HCV.

  • Adverse Effects

    • Common adverse effects include headache, fatigue, nausea, diarrhea, rash, and severe skin reactions.

  • Drug–Drug Interactions

    • Toxic effects or therapeutic loss may occur with other protease inhibitors or if combined with St. John’s wort.

Locally Active Antiviral Agents

  • Actions

    • Function by interfering with normal viral replication and metabolic processes at a local infection site.

  • Indications

    • Specifically prescribed for local viral infections.

  • Contraindications and Cautions

    • Not absorbed systemically; caution is needed with known allergies to topical drugs, and avoidance of application on open wounds.

  • Adverse Effects

    • Local burning, stinging, and discomfort may occur with topical applications.

Question #4

  • Question: Which antiviral drugs are not absorbed systemically?

    • Options:

      • Anti-hepatitis B agents

      • Locally active antiviral agents

      • Nucleoside agents

      • Fusion inhibitors

Answer to Question #4

  • Correct Answer: B. Locally active antiviral agents

  • Rationale: Locally active antiviral medications do not get absorbed systemically, necessitating caution in patients with known sensitivities to topical drugs.